Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib
Authors' conclusion
Higher paraoxonase activity over time was associated with significantly reduced risk of future MACE and malignancies (excluding NMSC), but not NMSC, in patients with RA receiving tofacitinib.
Study context
- Population
- Patients with rheumatoid arthritis (RA) receiving tofacitinib in 9 phase II/III studies and long-term extension studies9 phase II/III studies
- Participants
- 1,969 patients
- Comparison
- PON1 Q192R genotype and PON1 activity over time
- Outcome
- MACE and malignancy risk by time-varying PON1 enzyme activity
Methodological detailsfixed-effects meta-analysis, time-varying Cox proportional hazards regression
- Fixed-effects meta-analysis
- Time-varying Cox proportional hazards regression
Pooled result
As reported in the abstract
- Increased paraoxonase activity over time associated with lower risk of major adverse cardiovascular events (MACE)
- P < 0.001
- Increased paraoxonase activity over time associated with lower risk of malignancies (excluding NMSC)
- P ≤ 0.05
Further pooled results
Baseline PON1 activity by genotype
- RR vs QQ: significant positive association with paraoxonase activity; significant negative association with lactonase and arylesterase activity
- all P < 0.001
MACE by lactonase and arylesterase activity
- Similar trend as for paraoxonase
Original publication
Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J Rheumatol. Published 15 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →